주의력결핍 과잉행동장애(ADHD) 치료제 파이프라인 분석(2026년)(2분기 인사이트와 임상시험)

Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

The global attention deficit hyperactivity disorder (ADHD) drug pipeline is expanding steadily as pharmaceutical companies, biotechnology firms, and academic research organizations intensify efforts to develop safer, longer-acting, and more personalized therapies for ADHD. The growing prevalence of ADHD across children, adolescents, and adults, combined with increasing diagnosis rates and heightened awareness of neurodevelopmental disorders, has accelerated investment in innovative drug discovery. Drug pipeline analysis has become a critical strategic tool for evaluating investigational therapies, clinical development progress, regulatory milestones, competitive positioning, licensing opportunities, and commercialization potential across the ADHD treatment landscape.

Although stimulant medications such as methylphenidate and amphetamine formulations remain the standard treatment for ADHD, several unmet clinical needs continue to drive research. Current therapies may be associated with adverse effects, abuse potential, variable patient response, sleep disturbances, appetite suppression, and treatment discontinuation. Consequently, drug developers are increasingly focusing on next-generation stimulants, novel non-stimulant therapies, extended-release formulations, selective neurotransmitter modulators, and precision medicine approaches that offer improved efficacy with enhanced safety profiles.

The pipeline also reflects increasing innovation in drug delivery technologies. Evening-dosed extended-release formulations, once-daily therapies, abuse-deterrent formulations, and long-acting delivery systems are being developed to improve treatment adherence and provide consistent symptom control throughout the day. In parallel, researchers are evaluating therapies that address ADHD symptoms while minimizing cardiovascular effects, psychiatric adverse events, and dependence risks.

Artificial intelligence, genomic research, digital biomarkers, and real-world evidence are increasingly supporting ADHD drug development. These technologies improve target identification, patient stratification, clinical trial design, and treatment response prediction. Decentralized clinical trials, remote patient monitoring, and electronic clinical outcome assessments are also improving study efficiency and accelerating clinical development.

Growing recognition of adult ADHD, increasing healthcare expenditure, expanding neuroscience research funding, and supportive regulatory initiatives continue to strengthen the global ADHD drug development ecosystem. As numerous investigational therapies progress through preclinical and clinical development, the ADHD drug pipeline is expected to remain highly active throughout the forecast period.

Market Drivers

Expanding ADHD Patient Population

The growing prevalence and improved diagnosis of ADHD across pediatric and adult populations continue to increase demand for innovative therapeutic options.

Earlier diagnosis, greater public awareness, and improved access to psychiatric services are expanding the addressable patient population while encouraging pharmaceutical investment in new drug development.

Growing Demand for Non-Stimulant Therapies

Although stimulant medications remain highly effective, concerns regarding misuse, abuse potential, cardiovascular safety, and treatment tolerability have increased demand for non-stimulant alternatives.

Drug developers are investigating selective neurotransmitter modulators and novel mechanisms designed to improve long-term safety while maintaining clinical efficacy.

Advances in Drug Delivery Technologies

Extended-release formulations, delayed-release capsules, and innovative oral delivery systems are becoming major areas of pipeline innovation.

These technologies improve treatment adherence, reduce dosing frequency, and provide sustained symptom control throughout daily activities.

Increasing Investment in Neuroscience Research

Governments, biotechnology companies, pharmaceutical manufacturers, and academic institutions continue to increase investment in neurodevelopmental disorder research.

Growing funding supports discovery of new therapeutic targets, biomarker research, and advancement of promising pipeline candidates through clinical development.

Adoption of Precision Medicine

Precision medicine is gradually influencing ADHD drug development through biomarker identification, pharmacogenomics, and personalized treatment strategies.

Advanced analytical technologies are improving patient selection while supporting more efficient clinical development programs.

Market Restraints

Complex Clinical Development

ADHD clinical trials require extensive safety monitoring, long follow-up periods, and careful evaluation of cognitive and behavioral outcomes.

These requirements increase development timelines and overall research costs.

Regulatory Challenges

Novel ADHD therapies must demonstrate long-term efficacy, cardiovascular safety, abuse liability, and acceptable tolerability before receiving regulatory approval.

Comprehensive regulatory requirements may delay commercialization of promising drug candidates.

High Research and Development Costs

Drug discovery, multicenter clinical trials, manufacturing optimization, and regulatory submissions require substantial financial investment.

Smaller biotechnology companies may depend on strategic partnerships or licensing agreements to advance pipeline assets.

Technology and Segment Insights

By Development Phase

Phase II clinical trials account for a significant proportion of the ADHD pipeline as investigational therapies undergo evaluation for efficacy, dose optimization, pharmacokinetics, and safety.

Phase III development continues to expand as promising candidates approach regulatory submission, while preclinical and Phase I programs remain active through continuous introduction of novel compounds targeting new neurological pathways.

By Drug Class

Small-molecule therapies dominate the current ADHD pipeline due to established manufacturing capabilities and favorable pharmacological characteristics.

Extended-release stimulants continue to represent an important development area, while non-stimulant therapies are among the fastest-growing pipeline segments. Additional innovation includes prodrugs, selective neurotransmitter modulators, and novel oral formulations designed to improve therapeutic performance.

By Mechanism of Action

Traditional dopaminergic and noradrenergic therapies continue to represent the largest share of clinical development.

Pipeline diversification is increasing through investigation of selective receptor modulators and novel central nervous system targets intended to improve efficacy while reducing adverse effects and abuse potential.

By End User

Pharmaceutical companies remain the largest participants in ADHD drug development due to sustained investment in research, clinical trials, and commercialization.

Biotechnology companies are expanding rapidly by developing first-in-class therapies and innovative delivery technologies.

Academic institutions, contract research organizations, and neuroscience research centers continue to contribute significantly through early-stage discovery and collaborative clinical research.

Regional Insights

North America dominates the global ADHD drug pipeline due to its advanced pharmaceutical industry, strong biotechnology ecosystem, well-established clinical research infrastructure, and supportive regulatory environment. The United States continues to host the largest number of ADHD clinical development programs and remains a leading center for neuroscience innovation.

Europe represents another major market supported by extensive academic collaboration, established pharmaceutical manufacturers, and increasing investment in neurodevelopmental disorder research. Germany, the United Kingdom, France, Italy, and Spain continue to participate actively in multinational ADHD drug development programs.

Asia Pacific is expected to register the fastest growth during the forecast period. Expanding pharmaceutical manufacturing capabilities, improving regulatory frameworks, increasing healthcare expenditure, and growing ADHD awareness are encouraging greater clinical research activity across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually strengthening their clinical research capabilities through healthcare modernization, expanding participation in multinational clinical trials, and increased collaboration with international pharmaceutical companies.

Competitive and Strategic Outlook

The global ADHD drug pipeline is characterized by strong competition among multinational pharmaceutical companies, biotechnology firms, academic research institutions, and specialty neuroscience developers. Companies are actively pursuing differentiated therapies that provide improved efficacy, extended duration of action, enhanced safety, and reduced abuse potential.

Strategic collaborations, licensing agreements, acquisitions, and co-development partnerships continue to accelerate pipeline advancement while reducing development risk. Artificial intelligence, predictive analytics, pharmacogenomics, and digital clinical technologies are increasingly integrated into discovery and development processes to improve clinical success rates.

Future competition is expected to focus on first-in-class mechanisms of action, precision medicine approaches, long-acting formulations, digital-enabled clinical development, and innovative therapies capable of addressing unmet needs across pediatric and adult ADHD populations.

Conclusion

The global ADHD drug pipeline is expected to experience sustained expansion as pharmaceutical innovation continues to address significant unmet clinical needs in ADHD treatment. Growing diagnosis rates, increasing investment in neuroscience research, expanding non-stimulant therapeutic development, advances in drug delivery technologies, and adoption of precision medicine are expected to support long-term pipeline growth. Although regulatory complexity, high development costs, and lengthy clinical programs remain important challenges, continued innovation and strategic collaboration are expected to accelerate development of the next generation of ADHD therapies.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
  • 1.1.1 Definition of ADHD Drug Pipeline Intelligence
  • 1.1.2 Scope of Clinical and Commercial Assessment
  • 1.1.3 Key Questions Addressed in the Report
• 1.2 Key Pipeline Highlights
  • 1.2.1 Total Active Pipeline Assets
  • 1.2.2 Distribution by Clinical Phase
  • 1.2.3 Emerging Mechanistic Trends
  • 1.2.4 Novel Therapeutic Modalities
• 1.3 Strategic Insights
  • 1.3.1 Near-Term Approval Opportunities
  • 1.3.2 High-Impact Emerging Assets
  • 1.3.3 Competitive Positioning Trends
  • 1.3.4 Key Risks and Opportunities

2. Pipeline Overview

• 2.1 ADHD Drug Development Landscape
  • 2.1.1 Evolution of ADHD Therapeutics
  • 2.1.2 Current Treatment Paradigm
  • 2.1.3 Emerging Areas of Innovation
• 2.2 Global Pipeline Snapshot
  • 2.2.1 Total Pipeline Assets
  • 2.2.2 Active vs Dormant Programs
  • 2.2.3 Pipeline Growth Trends
  • 2.2.4 Historical Development Activity
• 2.3 Pipeline Distribution by Clinical Phase
  • 2.3.1 Preclinical Assets
  • 2.3.2 Phase I Assets
  • 2.3.3 Phase II Assets
  • 2.3.4 Phase III Assets
  • 2.3.5 Filed / Under Regulatory Review Assets
• 2.4 Pipeline Distribution by Sponsor Type
  • 2.4.1 Large Pharmaceutical Companies
  • 2.4.2 Specialty Pharmaceutical Companies
  • 2.4.3 Biotechnology Companies
  • 2.4.4 Academic and Research Institutions
• 2.5 Historical Pipeline Evolution
  • 2.5.1 New Candidate Entry Trends
  • 2.5.2 Advancement and Attrition Trends
  • 2.5.3 Regulatory Milestones Over Time

3. Disease & Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 ADHD Definition and Classification
  • 3.1.2 Epidemiology and Patient Population
  • 3.1.3 Disease Burden and Socioeconomic Impact
• 3.2 Pathophysiology and Disease Biology
  • 3.2.1 Neurotransmitter Dysregulation
  • 3.2.2 Dopaminergic Pathways
  • 3.2.3 Noradrenergic Pathways
  • 3.2.4 Emerging Neurobiological Targets
• 3.3 Current Treatment Landscape
  • 3.3.1 Stimulant Therapies
  • 3.3.2 Non-Stimulant Therapies
  • 3.3.3 Combination Approaches
  • 3.3.4 Behavioral and Adjunctive Therapies
• 3.4 Unmet Clinical Needs
  • 3.4.1 Treatment Resistance
  • 3.4.2 Long-Term Safety Concerns
  • 3.4.3 Pediatric and Adult Treatment Gaps
  • 3.4.4 Need for Novel Mechanisms

4. Mechanism & Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Dopamine Reuptake Inhibitors
  • 4.1.2 Norepinephrine Reuptake Inhibitors
  • 4.1.3 Monoamine Modulators
  • 4.1.4 Triple Reuptake Inhibitors
  • 4.1.5 Glutamatergic Pathway Modulators
  • 4.1.6 Orexin System Modulators
  • 4.1.7 Novel CNS Targets
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Established Mechanisms
  • 4.2.2 Emerging Mechanisms
  • 4.2.3 Novel Mechanisms in Early Development
  • 4.2.4 Mechanism Saturation Assessment
• 4.3 First-in-Class vs Best-in-Class Assessment
  • 4.3.1 First-in-Class Candidates
  • 4.3.2 Best-in-Class Candidates
  • 4.3.3 Differentiation Strategies
  • 4.3.4 Competitive Advantages by Mechanism
• 4.4 Modality Landscape
  • 4.4.1 Small Molecule Therapies
  • 4.4.2 Biologics
  • 4.4.3 RNA-Based Therapies
  • 4.4.4 Cell and Gene Therapies
  • 4.4.5 Digital and Combination Therapeutic Approaches

5. Clinical Development Intelligence

• 5.1 Clinical Trial Activity Overview
  • 5.1.1 Active Trials by Phase
  • 5.1.2 Historical Trial Growth
  • 5.1.3 Trial Initiation Trends
  • 5.1.4 Trial Completion Trends
• 5.2 Trial Design Benchmarking
  • 5.2.1 Study Design Patterns
  • 5.2.2 Randomization Strategies
  • 5.2.3 Comparator Selection
  • 5.2.4 Endpoint Selection
  • 5.2.5 Duration of Treatment Studies
• 5.3 Clinical Trial Metrics
  • 5.3.1 Sample Size Analysis
  • 5.3.2 Enrollment Trends
  • 5.3.3 Recruitment Timelines
  • 5.3.4 Geographic Distribution of Trials
• 5.4 Clinical Outcomes Assessment
  • 5.4.1 Efficacy Trends
  • 5.4.2 Safety and Tolerability Trends
  • 5.4.3 Adverse Event Profiles
  • 5.4.4 Treatment Adherence Patterns
• 5.5 Trial Failure and Discontinuation Analysis
  • 5.5.1 Historical Failure Rates
  • 5.5.2 Causes of Clinical Failure
  • 5.5.3 Development Delays
  • 5.5.4 Program Terminations

6. Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Report Segmentation

• 6.1 By Clinical Phase
  • 6.1.1 Preclinical Pipeline
  • 6.1.2 Phase I Pipeline
  • 6.1.3 Phase II Pipeline
  • 6.1.4 Phase III Pipeline
  • 6.1.5 Filed & Under Review Assets
• 6.2 By Mechanism of Action
  • 6.2.1 Dopamine Pathway Modulators
  • 6.2.2 Norepinephrine Pathway Modulators
  • 6.2.3 Mixed Monoamine Modulators
  • 6.2.4 Novel CNS Targets
  • 6.2.5 Other Emerging Mechanisms
• 6.3 By Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapeutics
  • 6.3.4 Gene Therapies
  • 6.3.5 Combination Therapeutics
• 6.4 By Patient Population
  • 6.4.1 Pediatric ADHD
  • 6.4.2 Adolescent ADHD
  • 6.4.3 Adult ADHD

7. Probability of Success & Risk Analysis

• 7.1 Clinical Success Probability Framework
  • 7.1.1 Methodology and Assumptions
  • 7.1.2 Phase Transition Model
  • 7.1.3 Historical Benchmarking
• 7.2 Probability of Success by Clinical Phase
  • 7.2.1 Preclinical to Phase I Transition
  • 7.2.2 Phase I to Phase II Transition
  • 7.2.3 Phase II to Phase III Transition
  • 7.2.4 Phase III to Approval Transition
• 7.3 Risk Assessment Framework
  • 7.3.1 Scientific Risk
  • 7.3.2 Clinical Risk
  • 7.3.3 Regulatory Risk
  • 7.3.4 Commercial Risk
• 7.4 Attrition Analysis
  • 7.4.1 Historical Attrition Rates
  • 7.4.2 Attrition by Mechanism
  • 7.4.3 Attrition by Modality
  • 7.4.4 Attrition by Sponsor Type
• 7.5 Risk-Adjusted Pipeline Valuation
  • 7.5.1 Probability-Weighted Asset Valuation
  • 7.5.2 Risk-Adjusted Market Opportunity
  • 7.5.3 Revenue Sensitivity Analysis

8. Launch Timeline & Commercial Potential

• 8.1 Regulatory Outlook
  • 8.1.1 Anticipated Regulatory Filings
  • 8.1.2 Expected Approval Timelines
  • 8.1.3 Expedited Review Opportunities
  • 8.1.4 Regulatory Challenges
• 8.2 Launch Timeline Analysis
  • 8.2.1 Expected Launch Sequence
  • 8.2.2 Geographic Launch Strategies
  • 8.2.3 Competitive Launch Windows
  • 8.2.4 First-to-Market Opportunities
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Market Expansion Potential
  • 8.3.2 Peak Sales Forecasts
  • 8.3.3 Revenue Opportunity by Asset
  • 8.3.4 Competitive Sales Dynamics

9. Competitive Pipeline Landscape

• 9.1 Industry Competitive Structure
  • 9.1.1 Market Concentration Analysis
  • 9.1.2 Leading Developers
  • 9.1.3 Emerging Challengers
  • 9.1.4 Innovation Leaders
• 9.2 Company-Wise Pipeline Strength
  • 9.2.1 Pipeline Breadth Assessment
  • 9.2.2 Pipeline Depth Assessment
  • 9.2.3 Clinical Stage Distribution
  • 9.2.4 Mechanism Diversity
• 9.3 Competitive Benchmarking
  • 9.3.1 Clinical Development Capabilities
  • 9.3.2 Regulatory Execution Capabilities
  • 9.3.3 Commercial Readiness
  • 9.3.4 Strategic Partnerships
• 9.4 Competitive Positioning Matrix
  • 9.4.1 Leaders
  • 9.4.2 Challengers
  • 9.4.3 Emerging Innovators
  • 9.4.4 Niche Developers

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Major Sponsors
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Major Sponsors
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Major Sponsors
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Major Sponsors
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Major Sponsors

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
• 11.2 Canada
  • 11.2.1 Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
• 11.3 Germany
  • 11.3.1 Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Key Sponsors
• 11.4 United Kingdom
  • 11.4.1 Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Key Sponsors
• 11.5 France
  • 11.5.1 Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Key Sponsors
• 11.6 Italy
  • 11.6.1 Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Key Sponsors
• 11.7 Spain
  • 11.7.1 Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Key Sponsors
• 11.8 China
  • 11.8.1 Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Key Sponsors
• 11.9 Japan
  • 11.9.1 Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Key Sponsors
• 11.10 India
  • 11.10.1 Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Key Sponsors
• 11.11 South Korea
  • 11.11.1 Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Key Sponsors
• 11.12 Australia
  • 11.12.1 Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Key Sponsors
• 11.13 Brazil
  • 11.13.1 Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Key Sponsors
• 11.14 Mexico
  • 11.14.1 Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Key Sponsors
• 11.15 Saudi Arabia
  • 11.15.1 Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Key Sponsors
• 11.16 South Africa
  • 11.16.1 Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Key Sponsors

12. Deals & Investment Landscape

• 12.1 Licensing and Collaboration Trends
  • 12.1.1 Regional Licensing Activity
  • 12.1.2 Global Licensing Agreements
  • 12.1.3 Technology Transfer Agreements
  • 12.1.4 Co-Development Partnerships
• 12.2 Mergers and Acquisitions
  • 12.2.1 Strategic Acquisitions
  • 12.2.2 Asset Acquisitions
  • 12.2.3 Portfolio Expansion Transactions
  • 12.2.4 Deal Value Trends
• 12.3 Financing and Investment Trends
  • 12.3.1 Venture Capital Funding
  • 12.3.2 Private Equity Investments
  • 12.3.3 Public Market Financing
  • 12.3.4 CNS Sector Investment Trends
• 12.4 Strategic Alliance Analysis
  • 12.4.1 Academia-Industry Collaborations
  • 12.4.2 Pharmaceutical-Biotech Partnerships
  • 12.4.3 Cross-Border Collaborations
  • 12.4.4 Emerging Alliance Models

13. Future Outlook & Strategic Insights

• 13.1 Future of ADHD Drug Development
  • 13.1.1 Emerging Scientific Trends
  • 13.1.2 Transformational Technologies
  • 13.1.3 Next-Generation Therapeutic Approaches
• 13.2 Future Clinical Development Trends
  • 13.2.1 Adaptive Trial Designs
  • 13.2.2 Digital Endpoint Integration
  • 13.2.3 Precision Psychiatry Approaches
  • 13.2.4 AI-Enabled Drug Development
• 13.3 Future Competitive Landscape
  • 13.3.1 Market Consolidation Trends
  • 13.3.2 Emerging Competitors
  • 13.3.3 Innovation Hotspots
  • 13.3.4 Competitive Threat Assessment
• 13.4 Strategic Recommendations for Stakeholders
  • 13.4.1 Pharmaceutical Companies
  • 13.4.2 Biotechnology Companies
  • 13.4.3 Investors and Venture Funds
  • 13.4.4 Contract Research Organizations
• 13.5 White Space Opportunities
  • 13.5.1 Novel Mechanistic Targets
  • 13.5.2 Adult ADHD Opportunities
  • 13.5.3 Pediatric Innovation Opportunities
  • 13.5.4 Combination Therapy Opportunities
• 13.6 Pipeline Outlook Through Forecast Period
  • 13.6.1 Expected Asset Progression
  • 13.6.2 Regulatory Milestone Outlook
  • 13.6.3 Commercialization Outlook
  • 13.6.4 Long-Term Growth Scenarios
• 13.7 Key Company Profiles
  • 13.7.1 Takeda Pharmaceutical Company
  • 13.7.2 Supernus Pharmaceuticals
  • 13.7.3 Otsuka Pharmaceutical
  • 13.7.4 Cingulate Inc.
  • 13.7.5 Axsome Therapeutics
  • 13.7.6 Neos Therapeutics
  • 13.7.7 Ironshore Pharmaceuticals
  • 13.7.8 Tris Pharma
  • 13.7.9 Novartis
  • 13.7.10 Johnson & Johnson

14. Methodology & Data Framework

• 14.1 Research Methodology
  • 14.1.1 Primary Research Framework
  • 14.1.2 Secondary Research Framework
  • 14.1.3 Data Validation Process
  • 14.1.4 Triangulation Methodology
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Register
  • 14.2.3 Company Pipeline Disclosures
  • 14.2.4 Regulatory Filings and Annual Reports
  • 14.2.5 Scientific Publications and Conference Proceedings
• 14.3 Pipeline Inclusion Criteria
  • 14.3.1 Asset Eligibility Criteria
  • 14.3.2 Phase Classification Rules
  • 14.3.3 Mechanism Classification Rules
  • 14.3.4 Sponsor Verification Process
• 14.4 Forecasting Framework
  • 14.4.1 Probability of Success Modeling
  • 14.4.2 Revenue Forecasting Methodology
  • 14.4.3 Launch Timing Assumptions
  • 14.4.4 Scenario and Sensitivity Analysis